Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Janux Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer - Management team bolstered with key appointment - $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 - In July, further strengthened balance sheet with approximately $60 million offering SAN DIEGO, August 8, 2023 – Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today reported financial results for the second quarter ended June 30, 2023, and provided a business..."
05/09/2023 8-K Quarterly results
Docs: "Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights -First patient dosed with EGFR-TRACTr in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -$316.9 million in cash and cash equivalents and short-term investments at end of first quarter 2023- SAN DIEGO, May 9, 2023 – Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. “Janux hit a major milestone in the f..."
03/10/2023 8-K Quarterly results
Docs: "Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -FDA clearance granted for Investigational New Drug application for EGFR-TRACTr - -$327.0 million in year-end cash and cash equivalents and short-term investments- SAN DIEGO, March 10, 2023 – Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “Janux made great strides in 2022 as we transiti..."
05/10/2022 8-K Quarterly results
Docs: "Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights -IND application recently submitted for PSMA-TRACTr - -Company remains on-track to submit IND application for EGFR-TRACTr in 2H 2022- -Merck nominates second target as part of strategic collaboration and license agreement- -Presented preclinical data for JANX007 and JANX008 at the 18th Annual Protein & Antibody Engineering Summit Boston Conference & Expo- -$361.2 million in cash and cash equivalents and short-term investments at end of first quarter 2022- SAN DIEGO, May 10, 2022 – Janux Therapeutics, Inc. , a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platf..."
03/18/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results -Company remains on-track to submit IND filings for two programs in 2022- -Board of Directors strengthened with key appointments- -$387.5 million in cash and cash equivalents and short-term investments at end of third quarter 2021- SAN DIEGO, November 9, 2021 – Janux Therapeutics, Inc. , a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today reported financial results for the quarter ended September 30, 2021. “In the third quarter, we continued to utilize our novel TRACTr and TRACIr platforms to advance our pipeline of next generation immunoth..."
08/10/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy